Nektar Therapeutics
NASDAQ:NKTR

Watchlist Manager
Nektar Therapeutics Logo
Nektar Therapeutics
NASDAQ:NKTR
Watchlist
Price: 0.9005 USD -2.99%
Market Cap: 166.1m USD
Have any thoughts about
Nektar Therapeutics?
Write Note

Nektar Therapeutics
Net Change in Cash

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Nektar Therapeutics
Net Change in Cash Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Change in Cash CAGR 3Y CAGR 5Y CAGR 10Y
Nektar Therapeutics
NASDAQ:NKTR
Net Change in Cash
-$34.8m
CAGR 3-Years
-164%
CAGR 5-Years
24%
CAGR 10-Years
0%
Johnson & Johnson
NYSE:JNJ
Net Change in Cash
$252m
CAGR 3-Years
N/A
CAGR 5-Years
5%
CAGR 10-Years
N/A
Bristol-Myers Squibb Co
NYSE:BMY
Net Change in Cash
$325m
CAGR 3-Years
N/A
CAGR 5-Years
-58%
CAGR 10-Years
-20%
Pfizer Inc
NYSE:PFE
Net Change in Cash
-$1.6B
CAGR 3-Years
N/A
CAGR 5-Years
-14%
CAGR 10-Years
N/A
Merck & Co Inc
NYSE:MRK
Net Change in Cash
$6B
CAGR 3-Years
31%
CAGR 5-Years
169%
CAGR 10-Years
N/A
Eli Lilly and Co
NYSE:LLY
Net Change in Cash
$988.2m
CAGR 3-Years
72%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Nektar Therapeutics
Glance View

Market Cap
166.1m USD
Industry
Pharmaceuticals

Nektar Therapeutics is a research-based biopharmaceutical company which engages in discovering and developing medicines in areas of unmet medical need. The company is headquartered in San Francisco, California and currently employs 740 full-time employees. The firm's research and development pipeline of new investigational drugs includes potential therapies for oncology, immunology and virology. In oncology, it is studying several immuno-oncology (I-O) drug candidates, including bempegaldesleukin, NKTR-255 and NKTR-262. In immunology, it is focused on addressing imbalances in the immune system to restore the body's self-tolerance mechanisms and achieve immune homeostasis. In autoimmune disorders, its IL-2 T-regulatory cell stimulator NKTR-358 is being clinically studied in systemic lupus erythematosus, ulcerative colitis, psoriasis and atopic dermatitis. Its programs in virology area include studying bempegaldesleukin in treating individuals affected with COVID-19, and a preclinical research collaboration with Gilead Sciences Inc. (Gilead) to test the combination of NKTR-255.

NKTR Intrinsic Value
0.6997 USD
Overvaluation 22%
Intrinsic Value
Price

See Also

What is Nektar Therapeutics's Net Change in Cash?
Net Change in Cash
-34.8m USD

Based on the financial report for Sep 30, 2024, Nektar Therapeutics's Net Change in Cash amounts to -34.8m USD.

What is Nektar Therapeutics's Net Change in Cash growth rate?
Net Change in Cash CAGR 10Y
0%

Over the last year, the Net Change in Cash growth was 15%. The average annual Net Change in Cash growth rates for Nektar Therapeutics have been -164% over the past three years , 24% over the past five years .

Back to Top